The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Quizartinib, venetoclax, and decitabine in patients with FLT3-ITD AML: a Phase I/II trial
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II study investigating the triplet combination of quizartinib, venetoclax, and decitabine in patients with treatment-naive or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). Of the 14 patients treated, 100% reached complete remission (CR), with 80% achieving normal count recovery and between 70% and 80% of treatment-naive patients achieving measurable residual disease (MRD)-negativity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer, Daiichi-Sankyo
